Abstract: The present invention relates to specific complexes comprising heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag1+, Ba2+, Pb2+, Gd3+ and Bi3+) and one or more hematein ligand(s). In particular, the invention relates to the use of the complexes as ex vivo contrast agents for a computed tomography scanning of a biological sample. Moreover, the invention relates to specific ex vivo methods for investigating a biological sample by means of computed tomography scanning methods, wherein the method comprises staining the biological sample with a solution comprising one or more of the complex(es); or wherein the method comprises staining the biological sample with a staining solution comprising hematein, and separately contacting the biological sample with one or more staining solution(s) comprising one or more heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag1+, Ba2+, Pb2+, Gd3+ and Bi3+).

Abstract: Provided are a novel acyclic carbene ligand for ruthenium complex formation; a ruthenium complex catalyst using the ligand; a method of using the complex as a catalyst in an ethylene-metathesis ethenolysis reaction; a method of preparing the ruthenium complex catalyst; and a method of preparing a linear alpha-olefin, the method including the step of reacting a linear or cyclic alkene compound in the presence of the ruthenium complex catalyst. The acyclic carbene ligand of the present invention and the ruthenium complex catalyst using the same have high selectivity and turnover number for terminal olefin formation in an ethylene-metathesis ethenolysis reaction, and thus linear ?-olefins may be prepared with a high yield.

Abstract: One-step methods for forming phosphate-based enzyme inhibitors are disclosed. Methods include reacting o-phosphorylethanolamine with an acyl chloride at acidic conditions. Acyl chlorides can be derivatized. The phosphate-based enzyme inhibitors can inhibit enzymes of the pentose phosphate pathway including D-ribose-5-phosphate aldose-ketose isomerase enzymes such as T. cruzi ribose 5-phosphate isomerase type B and D-ribulose-5-phosphate 3-epimerase enzymes. Methods can be used in forming pharmaceutical compositions for use in treatment of disease caused by kinetoplastid parasites including T. cruzi, T. brucei, and Leishmania spp.

Abstract: A thermally activated delayed fluorescent molecular material, a synthesizing method therefor, and an electroluminescent device are provided. The thermally activated delayed fluorescent molecular containing an indenobenzoselenoheteroaromatic ring donor is synthesized, so that an electron donating ability of the donor is increased, and an non-radiative transition rate is effectively inhibited, thereby increasing photo-luminescence quantum yield (PLQY) of the molecule; and increasing the twist angle between the electron donor and the electron acceptor. Meanwhile, electron cloud overlapping between highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) is reduced, thereby obtaining a smaller ?EST value. The organic electroluminescent device adopts the thermally activated delayed fluorescent molecular material prepared according to the synthesizing method, and thus has high luminous efficiency and long service life.

Abstract: Use of transition metal complexes of the formula (I) in organic light-emitting diodes where: M1 is a metal atom; carbene is a carbene ligand; L is a monoanionic or dianionic ligand; K is an uncharged monodentate or bidentate ligand selected from the group consisting of phosphines; CO; pyridines; nitriles and conjugated dienes which form a ? complex with M1; n is the number of carbene ligands and is at least 1; m is the number of ligands L, where m can be 0 or ?1; o is the number of ligands K, where o can be 0 or ?1; where the sum n+m+o is dependent on the oxidation state and coordination number of the metal atom and on the denticity of the ligands carbene, L and K and also on the charge on the ligands carbene and L, with the proviso that n is at least 1, and also an OLED comprising these transition metal complexes, a light-emitting layer comprising these transition metal complexes, OLEDs comprising this light-emitting layer, devices comprising an OLED according to the present invention, and specific tr

Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

Abstract: The present application discloses a 3,3,3?,3?-tetramethyl-1,1?-spirobiindane-based phosphine ligand, an intermediate, a preparation method and uses thereof. The compound of phosphine ligand is a compound having a structure represented by formula I or formula II, or an enantiomer, a raceme, or diastereomer thereof. The phosphine ligand can be prepared via a preparation scheme in which the cheap and easily available 6,6?-dihydroxyl-3,3,3?,3?-tetramethyl-1,1?-spirobiindane is used as a raw material and the compound represented by formula III serves as the key intermediate. The new phosphine ligand developed by the present application can be used in catalytic organic reaction, in particular as a chiral phosphine ligand that is widely used in many asymmetric catalytic reactions including asymmetric hydrogenation and asymmetric allyl alkylation, and thus it has economic practicability and industrial application prospect.

Abstract: A zinc ascorbate glycinate co-salt having a formula of MC8H11NO8 and a suggested structure of: Formula (I). Where M is Ca, Mg, or Zn. The divalent metal ascorbate glycinate co-salt is formed as a powder having a metal content of about 8% to about 21% on an anhydrous basis and containing between 0.0-20.0% water.

Abstract: Being used for drug modification, the multi-arm single molecular weight polyethylene glycol and an active derivative thereof provided herein can effectively improve the solubility, stability, and immunogenicity of the drugs, improve the absorption of the drugs in vivo, prolong the half-life of the drugs, and increase bioavailability, enhance efficacy, and reduce toxic and side effects of the drugs. A gel formed from the active derivative of the multi-arm single molecular weight polyethylene glycol provided herein can be used for the preparation of controlled release drugs so as to prolong the action time of the drugs, thereby reducing the number of administrations and improving patient compliance.

Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Abstract: The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy and having improved properties.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: Provided herein are integrated methods and systems for the production of acrylamide and acrylonitrile compounds and other compounds from at least beta-lactones and/or beta-hydroxy amides.

Abstract: A method of fixating carbon dioxide (CO2) to a substituted oxazolidinone. The method includes mixing a metal-organic framework (MOF), a co-catalyst, at least one para-substituted aromatic amine, and at least one epoxide to form a mixture. The method further includes contacting the mixture with a gas stream containing CO2 to react the CO2 in the gas stream with the epoxide and para-substituted aromatic amine to form a substituted oxazolidinone mixture. The MOF is a UiO-66-X MOF, where X is of formula (I) wherein at least one of R1 to R4 is an allyloxy group, and R1 to R4 are independently an allyloxy group or a hydrogen.

Abstract: There is provided a novel optically active bisphosphinomethane useful as a ligand for an asymmetric catalyst, excellent in oxidation resistance in air, and easy in handling. There is also provided a transition metal complex using the optically active bisphosphinoraethane having excellent asymmetric catalytic ability as a ligand. The optically active bisphosphinomethane is represented by the general formula (1), and the transition metal complex has the optically active bisphosphinomethane as a ligand. (In the formula, R1 represents an adamantyl group; R2 represents a branched alkyl group having 3 or more carbon atoms; and * represents an asymmetric center on a phosphorus atom.

Abstract: The present disclosure belongs to the technical field of organic materials, and provides an organic compound. An adamantane spirofluorenyl and an anthryl are connected to obtain a novel compound for an organic electroluminescence device. In this compound, adamantane in the adamantane spirofluorene greatly increases the density of electron clouds on the fluorenyl through the hyperconjugation effect, which reduces the HOMO energy level of the compound and improves the hole migration ability. Both the adamantane spirofluorene and the anthryl have high hole mobility, so when the two are connected, the overall hole mobility of molecules is further improved, which is beneficial to reducing the working voltage of the device and improving the luminous efficiency. The present disclosure further provides an electronic component and an electronic apparatus including the compound. The organic compound can improve the performance of the electronic component.

Abstract: The invention relates to a crosslinking compound of formula (I) In particular, the present invention relates to a liquid composition comprising a monomer, a (meth)acrylic polymer and at least one crosslinking compound of formula (I). This liquid composition may be used in the form of a syrup and in particular in the form of a syrup for impregnating fibers or fibrous material. The invention also relates to a pseudo-thermoplastic material obtained after polymerization of the liquid composition being at least partially crosslinked. The invention also relates to a process for manufacturing such a liquid composition. The invention also relates to a process for impregnating a long-fiber fibrous substrate with said liquid composition. The invention also relates to a fibrous substrate impregnated with said liquid composition which is useful for manufacturing composite parts.

Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I) in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to a method for the metal-free preparation of a biaryl compound by a photosplicing reaction and its use in the preparation of chemical compounds, preferably of active ingredients e.g. in the fields of pharmaceuticals and agrochemicals. In particular, it refers to a method for the regiocontrolled preparation of a biaryl compound of formula (I): Ar—Ar? by photochemically reacting a precursor compound of formula (II): Ar—L—Ar? to form a biaryl compound of general formula: Ar—L—Ar?(II)?Ar—Ar? (I) wherein Ar and Ar?, independently of each other, represent an unsubstituted or substituted C6-C20 aryl group or a heteroaryl group with 5-20 ring atoms selected from carbon, nitrogen, oxygen and sulfur, and L represents a group —X—Y—Z— as defined herein. The biaryl compounds are generally suitable as intermediates or key building blocks in a very broad spectrum of organic chemical syntheses and their respective utilities.